NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) on Tuesday said it has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla over patent litigation related to Vyndamax, its treatment for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Under the agreements, the effective U.S. patent expiry for Vyndamax has been extended to June 1, 2031, subject to ongoing litigation outcomes. Pfizer had earlier expected a revenue decline beginning in 2029 due to patent expiry, but now anticipates relatively stable U.S. sales from 2028 through mid-2031.
Vyndamax remains the market leader in ATTR-CM treatment, accounting for about 75% of prescription volume. The once-daily therapy has demonstrated significant reductions in all-cause mortality and cardiovascular-related hospitalizations.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
